
https://www.bioregio-stern.de/en/aktuelles/aktuelles (17.02.2019)
News
Title | Content | Date |
---|---|---|
How sleep strengthens the immune system | Scientists at the University of Tübingen discover new mechanism that supports our immune system during sleep | 12.02.2019 |
CureVac Appoints Stefan Mueller, Ph.D., as Vice President Preclinical | Drug development veteran to focus on advancing the company’s preclinical portfolio of programs in naturally optimized mRNA | 04.02.2019 |
Novel unusual sugar from cyanobacteria acts as natural herbicide | Chemists and microbiologists at Tübingen University discover sugar molecule that inhibits the growth of plants and microorganisms and is harmless to human cells ‒ An alternative to controve | 01.02.2019 |
Blockstart makes SMEs stronger with blockchain solutions | The new European project Blockstart helps small- to medium-sized enterprises (SMEs) strengthen their competitive positions through the use of blockchain technology. | 30.01.2019 |
A safer way to correct faulty DNA | University of Tübingen researchers take RNA editing a step closer to treating hereditary diseases | 28.01.2019 |
CureVac Appoints Dimitris Voliotis, M.D., Dr. med., as Chief Development Officer | Drug development veteran to lead CureVac’s global product development efforts as the company looks to advance its pipeline of mRNA-based products | 28.01.2019 |
Second Codex4SMEs double session held at IBBL | IBBL (Integrated Biobank of Luxembourg) is pleased to be hosting the second Codex4SMEs double session at its premises in Dudelange, Luxembourg. | 23.01.2019 |
From Stuttgart to the world: Fraunhofer IPA turns 60 | "Future is our product" is the motto of the Fraunhofer Institute for Manufacturing Engineering and Automation IPA. | 21.01.2019 |
CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants Against RSV | CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced that the U.S. | 08.01.2019 |
Atriva Therapeutics announces first closing of series A financing round | Funds to advance antiviral lead product ATR-002 into clinical trials | 03.01.2019 |